MAAT.PA Maat Pharma SA

Healthcare Biotechnology Euronext Paris
1.09 EUR
Close of Nov 7, 2026
0.9030 8.62
Market cap
EUR 20.5M
P/E
-
P/B
10.67x
ROE
-
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is MAAT.PA undervalued?

Graham number

The Graham number of Maat Pharma SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Maat Pharma SA fundamental analysis

3 of 11 checks passed

ROE 0/2

Negative ROE (-41.61%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-31.87%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 1/2

The stock's PBV ratio (2.84x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

DER 2/2

The stock has a low debt to equity ratio (42%), which means it has a small amount of debt compared to the ownership it holds

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

Assets Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Graham Number 1/1

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

Dividend Growth 0/2

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Dividend 0/2

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Buffet Intrinsic Value 0/1

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Maat Pharma SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Maat Pharma SA

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic…

Full company profile